Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Holding BBIO?
Track your performance easily
BBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$21.62 - $44.32
Previous Close$26.49
Volume4.20M
Average Volume (3M)2.06M
Market Cap
$4.95B
Enterprise Value$5.14B
Total Cash (Recent Filing)$266.32M
Total Debt (Recent Filing)$446.65M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Feb 20, 2025EPS Estimate
-$1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.41
Shares Outstanding188,989,802
10 Day Avg. Volume1,642,275
30 Day Avg. Volume2,060,202
Standard Deviation0.24
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-4.07
Price to Sales (P/S)22.75
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.62
Enterprise Value/Gross Profit750.28
Enterprise Value/Ebitda-14.11
Forecast
1Y Price Target
$49.15Price Target Upside85.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
BridgeBio Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical BenefitsAcoramidis showed clear benefits on cardiovascular outcomes, significantly reducing cardiovascular-related hospitalization, improving survival, and preserving functional capacity and quality of life for patients in need.
Market AcceptanceAcoramidis' lower gross pricing compared to Tafamidis potentially makes it attractive to payers, which could positively influence its market acceptance.
Regulatory ApprovalFDA approval of Acoramidis with its indication listing CV death and CV hospitalization benefit is seen as a major positive for BBIO, removing concerns around regulatory headwinds and milestone payments.
Bears Say
Competitive LandscapeThe biggest challenge for Attruby is Pfizer's intellectual property case for tafamidis, which may impact its competitive edge.
Financial HealthBalance sheet concerns and spend rate add further risk to a complicated story.
Regulatory HurdlesA potential announcement of an Acoramidis AdCom could drive ~30-40% downside in BBIO.
---
Ownership Overview
20.69% Insiders
15.72% Mutual Funds
46.04% Other Institutional Investors
4.27% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $21.62 and its highest was $44.32 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
Currently, no data Available
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is Feb 20, 2025 which is in 61 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Nov 12, 2024. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$1.003 by $0.143.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -$1.13.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 188,989,800 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.86 in its last earnings report, beating expectations of -$1.003. Following the earnings report the stock price went down -5.743%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 640M.
---
BridgeBio Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.15 (85.54% Upside)
$49.15 (85.54% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 5.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.52%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Month Forecast
Average Price Target
$49.15
▲(85.54% Upside)
Technical Analysis
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+18.90%
reiterated a buy rating 27 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +18.90% per trade.
---